Suppr超能文献

相似文献

4
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Int J Pharm. 2006 Jan 3;307(1):93-102. doi: 10.1016/j.ijpharm.2005.10.010. Epub 2005 Nov 21.
5
Poly(2-ethyl-2-oxazoline) (POx) as Poly(ethylene glycol) (PEG)-Lipid Substitute for Lipid Nanoparticle Formulations.
Small. 2025 Apr;21(16):e2411354. doi: 10.1002/smll.202411354. Epub 2025 Mar 19.
6
Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines.
Front Immunol. 2020 Oct 12;11:567365. doi: 10.3389/fimmu.2020.567365. eCollection 2020.
7
POZylation: a new approach to enhance nanoparticle diffusion through mucosal barriers.
Nanoscale. 2015 Aug 28;7(32):13671-9. doi: 10.1039/c5nr03178h. Epub 2015 Jul 27.
8
Complement opsonization of nanoparticles: Differences between humans and preclinical species.
J Control Release. 2021 Oct 10;338:548-556. doi: 10.1016/j.jconrel.2021.08.048. Epub 2021 Sep 2.
9
Shielding Therapeutic Drug Carriers from the Mononuclear Phagocyte System: A Review.
Crit Rev Ther Drug Carrier Syst. 2016;33(6):489-567. doi: 10.1615/CritRevTherDrugCarrierSyst.2016012303.
10
Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
Adv Mater. 2022 Feb;34(8):e2107070. doi: 10.1002/adma.202107070. Epub 2022 Jan 11.

引用本文的文献

1
PEGylation technology: addressing concerns, moving forward.
Drug Deliv. 2025 Dec;32(1):2494775. doi: 10.1080/10717544.2025.2494775. Epub 2025 Apr 23.

本文引用的文献

1
Complement in human disease: approved and up-and-coming therapeutics.
Lancet. 2024 Jan 27;403(10424):392-405. doi: 10.1016/S0140-6736(23)01524-6. Epub 2023 Nov 15.
2
Activation of the complement system by nanoparticles and strategies for complement inhibition.
Eur J Pharm Biopharm. 2023 Dec;193:227-240. doi: 10.1016/j.ejpb.2023.11.006. Epub 2023 Nov 8.
4
Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins.
Nat Nanotechnol. 2024 Feb;19(2):246-254. doi: 10.1038/s41565-023-01514-z. Epub 2023 Oct 5.
5
Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions.
J Control Release. 2023 Apr;356:115-129. doi: 10.1016/j.jconrel.2023.02.022. Epub 2023 Mar 2.
6
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.
Nat Rev Mater. 2023;8(4):282-300. doi: 10.1038/s41578-022-00529-7. Epub 2023 Jan 19.
7
A brief history of long circulating nanoparticles.
Adv Drug Deliv Rev. 2022 Sep;188:114396. doi: 10.1016/j.addr.2022.114396. Epub 2022 Jul 5.
8
Complement opsonization of nanoparticles: Differences between humans and preclinical species.
J Control Release. 2021 Oct 10;338:548-556. doi: 10.1016/j.jconrel.2021.08.048. Epub 2021 Sep 2.
10
C1q binding to surface-bound IgG is stabilized by C1rs proteases.
Proc Natl Acad Sci U S A. 2021 Jun 29;118(26). doi: 10.1073/pnas.2102787118.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验